Cargando…

Effects of Ectopic Expression of NGAL on Doxorubicin Sensitivity

Neutrophil gelatinase-associated lipocalin (NGAL, a.k.a Lnc2) is a member of the lipocalin family which has diverse roles including stabilizing matrix metalloproteinase-9 from auto-degradation and as siderocalins which are important in the transport of iron. NGAL also has important biological functi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chappell, William H., Abrams, Stephen L., Montalto, Giuseppe, Cervello, Melchiorre, Martelli, Alberto M., Candido, Saverio, Libra, Massimo, Polesel, Jerry, Talamini, Renato, Arlinghaus, Ralph, Steelman, Linda S., McCubrey, James A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2012
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717946/ https://www.ncbi.nlm.nih.gov/pubmed/23100449

Ejemplares similares

Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer
por: Candido, Saverio, et al.
Publicado: (2014)

Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
por: Chappell, William H., et al.
Publicado: (2020)

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
por: Duda, Przemysław, et al.
Publicado: (2020)

GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals
por: Abrams, Stephen L., et al.
Publicado: (2021)

Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression
por: Steelman, Linda S., et al.
Publicado: (2017)

Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells
por: Taylor, Jackson R., et al.
Publicado: (2011)

Cancer therapy and treatments during COVID-19 era
por: Akula, Shaw M., et al.
Publicado: (2020)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer
por: Falzone, Luca, et al.
Publicado: (2016)

Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells
por: McCubrey, James A., et al.
Publicado: (2016)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
por: McCubrey, James A., et al.
Publicado: (2012)

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
por: Davis, Nicole M., et al.
Publicado: (2014)

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
por: Cervello, Melchiorre, et al.
Publicado: (2012)

Advances in Targeting Signal Transduction Pathways
por: McCubrey, James A., et al.
Publicado: (2012)

Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
por: McCubrey, James A., et al.
Publicado: (2017)

GSK-3 as potential target for therapeutic intervention in cancer
por: McCubrey, James A., et al.
Publicado: (2014)

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
por: McCubrey, James A., et al.
Publicado: (2022)

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells
por: Cervello, Melchiorre, et al.
Publicado: (2013)

Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells
por: Abrams, Stephen L., et al.
Publicado: (2017)

Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
por: McCubrey, J A, et al.
Publicado: (2014)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
por: Augello, Giuseppa, et al.
Publicado: (2020)

New landscapes and horizons in hepatocellular carcinoma therapy
por: Cervello, Melchiorre, et al.
Publicado: (2020)

Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells
por: Cusimano, Antonella, et al.
Publicado: (2014)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma
por: Falzone, Luca, et al.
Publicado: (2016)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
por: Sokolosky, Melissa L., et al.
Publicado: (2011)

NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance
por: Emma, M R, et al.
Publicado: (2016)

Exploiting p53 Status to Enhance Effectiveness of Chemotherapy by Lowering Associated Toxicity
por: Steelman, Linda S., et al.
Publicado: (2011)

Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer
por: Pappalardo, Francesco, et al.
Publicado: (2016)

Cutaneous melanoma: From pathogenesis to therapy (Review)
por: Leonardi, Giulia C., et al.
Publicado: (2018)

Bioinformatic analysis of the LCN2–SLC22A17–MMP9 network in cancer: The role of DNA methylation in the modulation of tumor microenvironment
por: Candido, Saverio, et al.
Publicado: (2022)

Emerging targeted therapies for melanoma treatment (Review)
por: RUSSO, ANGELA, et al.
Publicado: (2014)

APR-246—The Mutant TP53 Reactivator—Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells
por: McCubrey, James Andrew, et al.
Publicado: (2022)

MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
por: Salemi, Rossella, et al.
Publicado: (2018)

Analysis of the B-RAF(V600E) mutation in cutaneous melanoma patients with occupational sun exposure
por: CANDIDO, SAVERIO, et al.
Publicado: (2014)

Bevacizumab in the treatment of NSCLC: patient selection and perspectives
por: Russo, Alessia E, et al.
Publicado: (2017)

Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma
por: Bevelacqua, Valentina, et al.
Publicado: (2012)

NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells
por: Hu, Limei, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_vbbbire7sfmcvt568ug4p5odli